Coverage appeal AI
Claimable
Claimable’s patient appeal workflow, including sponsored referrals, documents patient editing and approval before delivery. Enterprise analytics have a separate scope. Sponsorship and contradictory sharing language require scrutiny, with implementation unverified.
Checklist assessment dated October 30, 2026. Independent confirmation is incomplete. Hugo has not personally verified this service.
Agency checklist · October 30, 2026
Mixed 7 of 12 yes
Document-based draft. Independent confirmation is incomplete. Hugo has not personally verified this service.
Assessed function: Claimable patient appeal workflow (patient-facing AI-drafted insurance appeals, including pharma/provider-sponsored referrals); enterprise analytics for pharma and health systems not assessed
A no can mean missing documentation or institution-dependent control; it does not by itself establish harmful behavior. These categories are not clinical safety or product-quality ratings.
- Public documents do not establish actual product behavior.
- The independent review screened rules and selected evidence; it did not replicate all twelve answers for this tool.
See all twelve answers and their evidence
| Question | Answer | Evidence / review | Source and reasoning |
|---|---|---|---|
| 1. Told it is AI | Yes | documented Not independently replicated | utilizing our artificial intelligence driven software solutionSource AI is disclosed in the Terms of Service (Service section) and throughout the site. A separate in-product consent screen was not observed (login required). |
| 2. Operator and model maker named | No | not-documented Not independently replicated | Quotation not recorded; evidence repair pending. Source Claimable, Inc. is named as operator. No public source names the maker of the language model. The AI blog says only 'custom-built technology', 'large language models' and NVIDIA Inception membership. |
| 3. Patient chooses to use it | Yes | documented Not independently replicated | account holders themselves and individuals (e.g. child or elderly parent) whom account holders choose to assist in filing of appealsSource Patient creates an account and completes intake. Referrals from pharma, pharmacies or providers exist (for-pharma FAQ: 'invited through direct referral or self-enrollment'), but the patient still starts and approves the appeal. |
| 4. Patient sets the task | Yes | documented Not independently replicated | Patients remain the decision-makers, and AI simply structures their story with supporting evidence.Source Statement is from the partner-facing page, not a binding document. Sponsored programs are disclosed 'during consent' per the same page. Whether sponsored flows steer patients toward a sponsor's drug was not tested. |
| 5. Patient can decline or stop | Yes | documented Not independently replicated | account holders themselves and individuals (e.g. child or elderly parent) whom account holders choose to assist in filing of appealsSource Self-started rule applied. Also: 'nothing is sent without their approval' (for-pharma FAQ). |
| 6. Patient sees the AI output | Yes | documented Not independently replicated | you review the final document before anything is submittedSource Patient sees the AI-drafted appeal before submission. |
| 7. Patient can correct or challenge | Yes | documented Not independently replicated | Patients verify accuracy, make edits, and authorize submissionSource Edit and flag route documented in partner FAQ and for-providers page ('can make any changes before it's sent'); the AI blog says patients can 'mark it for further examination'. |
| 8. Patient can get a copy | No | not-documented Not independently replicated | Quotation not recorded; evidence repair pending. Source Privacy policy lets users 'review and update certain Claimable account information'. No export or download of the appeal or data is documented. The Data Request Form is mentioned only for marketing opt-out. |
| 9. Patient can delete | Yes | documented Not independently replicated | You can request that we delete your account by contacting us with your account deletion request or deleting your account through the Services.Source Terms say Claim Data 'may be deleted and not be retrievable' on account deletion, but the same Terms grant Claimable a perpetual, irrevocable license to Claim Data. What survives deletion is unclear. |
| 10. Training or sale does not override patient choice | No | documented Not independently replicated | when aggregated and anonymized, any other purpose in any form, format, or media that we chooseSource Binding Terms (section 6) and Privacy ('research and development', sharing de-identified data) allow reuse. The AI blog says the AI 'is trained to recognize patterns in successful appeals'. No opt-out is documented. The safe-sharing blog says data is not sold or shared, which conflicts with the binding documents. Answered by the binding documents. |
| 11. Patient can run it or take it elsewhere | No | not-documented Not independently replicated | Quotation not recorded; evidence repair pending. Source Vendor-hosted only. Terms grant a revocable, non-transferable right to use the Service. No self-hosting or portability. |
| 12. No advertising or data business | No | documented Not independently replicated | We may use this aggregated, de-identified or otherwise anonymized data and share it with third parties for our lawful business purposesSource Privacy also allows sharing with 'licensors or partners' for 'their analysis or marketing purposes subject to your consent', and CCPA 'sale' of device data. The for-pharma page markets 'aggregate analytics' of insurer denial patterns to manufacturers. Terms allow fees to be waived when sponsored by pharma or providers. |
Initial coding: Claude Sonnet helpers, compiled by Claude Opus 5.5 (Anthropic). Selective review and corrections: GPT-6 Astra (OpenAI). Editor: Hugo Campos. Acceptance of corrections is not product verification.
Checklist rules · Independent review and limitations · Later evidence follow-up
Earlier v1.3 assessment and control finding
Historical assessment under different rules. It does not set the current checklist zone.
Agency finding, before method v1.3
Potentially agency-expanding, with sponsorship-alignment caveat
Legacy editorial placement, pre-method: 72
This profile has not yet been reviewed under the published method. Its finding and any number are editorial placements made before the method existed.
- Evidence
- Documentary review. Public sources only, no hands-on testing by HugoScore.
- Review status
- AI draft. No person has settled the findings.
Earlier evidence and assessment
The sections below preserve the earlier review. Its classifications and provenance are historical; the checklist above gives the current draft classification.
Earlier finding · Legacy editorial placement, pre-method: 72
Method v1.3. The control line is evidence for how the agency finding arose, not a quality score. Legacy editorial placement, pre-method: 72. Not comparable with v1.3 positions.
Potentially agency-expanding, with sponsorship-alignment caveat
Claimable’s patient appeal workflow, including sponsored referrals, documents patient editing and approval before delivery. Enterprise analytics have a separate scope. Sponsorship and contradictory sharing language require scrutiny, with implementation unverified.
Patient agency
How this tool changes agency
drafting and delivery can make contesting a denial practically possible. Evidence-backed argument is a documented product claim, not verified citation quality or proof of broader critical understanding.
Consent presentation, independent output-use rights, control outside the supported appeal goal, and actual partner data flows.
Patient agency assessment
Who sets and changes the goal?
the documented approval gate supports patient direction within the appeal task. Provider referral and sponsorship do not erase that gate. Authority over a different treatment goal or enterprise strategy is not established.
What can the patient understand, question, or do?
drafting and delivery can make contesting a denial practically possible. Evidence-backed argument is a documented product claim, not verified citation quality or proof of broader critical understanding.
Can the patient evaluate the conditions of use?
the public controls are meaningful, but contradictory sharing language and unobserved consent limit confidence in how patients evaluate the service's conditions. Commercial interests may coincide with a chosen appeal without encompassing all patient interests.
Text findings
Conditions of use
Published controls and their limits
the public controls are meaningful, but contradictory sharing language and unobserved consent limit confidence in how patients evaluate the service's conditions. Commercial interests may coincide with a chosen appeal without encompassing all patient interests.
What remains unknown?
Not tested or not established
Consent presentation, independent output-use rights, control outside the supported appeal goal, and actual partner data flows.
Who evaluated this?
AI-assisted public-source draft
Vendor statements describe published conditions, not independently verified behavior. No clinical, security, accessibility, or legal validation is claimed. Earlier evidence remains dated in the report and history.
Sources checked
- https://www.getclaimable.com/for-providers
- https://www.getclaimable.com/for-pharma
- https://www.getclaimable.com/provider-service-agreement
- https://www.getclaimable.com/privacy-policy
Source-specific findings and retrieval limitations are recorded in the full report.
Earlier review provenance
Criteria
CAIHL-derived HugoScore framework and September 7 qualitative review priorities. Draft v1.2 numerical anchors remain unadopted.
Reviewer
AI-assisted public-source reassessment prepared in OpenAI Codex.
AI / model
OpenAI Codex / GPT-6
Human review
Hugo Campos authorized publication of these AI-assisted draft reassessments on September 8, 2026. This does not claim comprehensive human verification of every finding.
Review date
2026-09-08
Limitations
Consent presentation, independent output-use rights, control outside the supported appeal goal, and actual partner data flows. No live product use, patient-data upload, account creation, code audit, clinical evaluation, or independent implementation validation.
Earlier review method
Focused public-source reassessment using CAIHL: patient authority, critical capacity, and informed control. Existing evidence plus one focused primary-source pass and at most one targeted follow-up. No live product testing. Numerical scores remain provisional editorial placements, not a new calculation.
Document-based draft · Medium for published documentation, low for implementation (AI-assisted draft)